@article{2b746ac625e046cc84fca351958d9623,
title = "Aggressive Treatment for Severe Forms of Familial Hypercholesterolemia",
keywords = "ASCVD, LDL-C, PCSK9 inhibitor, evolocumab, familial hypercholesterolemia, lipid-lowering therapy, safety",
author = "Duell, {P. Barton} and Sergio Fazio",
note = "Funding Information: Dr. Duell has been a consultant for AstraZeneca, Esperion, RegenxBio, Regeneron, Retrophin, and Akcea; and has received institutional grants from Retrophin, Regeneron, and Regenxbio. Dr. Fazio has been a consultant for Amgen, Amarin, Novo, and AstraZeneca.",
year = "2020",
month = feb,
day = "18",
doi = "10.1016/j.jacc.2020.01.001",
language = "English (US)",
volume = "75",
pages = "575--577",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "6",
}